Sana Biotechnology plans IND filing, targets Phase 1/2 start this year for SC451 type 1 diabetes therapy - SANA News | RalliesSana Biotechnology plans IND filing, targets Phase 1/2 start this year for SC451 type 1 diabetes therapy
S
SANA• SC451 diabetes program moves toward clinical testing
- Sana set to file an IND application for SC451, a hypoimmune stem cell-derived islet therapy for type 1 diabetes.
- Phase 1/2 trial planned as early as this year, positioning SC451 as a potential one-time treatment.
- Program goal targets long-term normal blood glucose without insulin therapy or immunosuppression.
•
